A Double-Blind, Placebo-Controlled Study of a Combination Product (BCI-024 and BCI-049) in Patients With Major Depressive Disorder (MDD)

Trial Profile

A Double-Blind, Placebo-Controlled Study of a Combination Product (BCI-024 and BCI-049) in Patients With Major Depressive Disorder (MDD)

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2015

At a glance

  • Drugs Buspirone/melatonin (Primary) ; Buspirone
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Apr 2010 Results reported in a BrainCells media release.
    • 27 Jul 2009 Results have been presented at NCDEU 2009, according to a BrainCells Inc media release.
    • 29 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top